154 related articles for article (PubMed ID: 19476263)
21. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
22. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
Prescrire Int; 2008 Dec; 17(98):236. PubMed ID: 19422148
[No Abstract] [Full Text] [Related]
24. Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
Tan MH; Tan CS; Lim WY
J Clin Oncol; 2009 Mar; 27(8):1342; author reply 1342-3. PubMed ID: 19188671
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Kumar V; Ghosh B; Raina UK; Goel N
Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
[No Abstract] [Full Text] [Related]
26. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic agents in breast cancer.
Salter JT; Miller KD
Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
[No Abstract] [Full Text] [Related]
28. [Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].
Manikhas GM; Korolenko VO; Al'-Nekhmi AA; Antimonik NIu
Vopr Onkol; 2010; 56(5):613-6. PubMed ID: 21137245
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.
Kernt M; Neubauer AS; Kampik A
Acta Ophthalmol Scand; 2007 Feb; 85(1):119-20. PubMed ID: 17244226
[No Abstract] [Full Text] [Related]
30. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
Hurwitz HI; Honeycutt W; Haley S; Favaro J
Clin Colorectal Cancer; 2006 May; 6(1):66-9. PubMed ID: 16796794
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
32. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
Escudier B
J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
[No Abstract] [Full Text] [Related]
33. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
35. [Bevacizumab and lung cancer: eligible patients in daily practice].
Lagnien-Gaume V; Jehl J; Manzoni P; Jacoulet P; Gainet-Brun M; Metzger F; Pernet D; Polio JC; Pugin JF; Corgne J; Amoros C; Dalphin JC; Westeel V
Rev Mal Respir; 2011 Jan; 28(1):25-31. PubMed ID: 21277471
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
[TBL] [Abstract][Full Text] [Related]
37. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Farhat MH; El-Saghir NS; Shamseddine AI
Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
[TBL] [Abstract][Full Text] [Related]
38. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.
Flieger D; Hainke S; Fischbach W
Ann Hematol; 2006 Sep; 85(9):631-2. PubMed ID: 16807748
[No Abstract] [Full Text] [Related]
39. Bevacizumab: current updates in treatment.
Van Meter ME; Kim ES
Curr Opin Oncol; 2010 Nov; 22(6):586-91. PubMed ID: 20811277
[TBL] [Abstract][Full Text] [Related]
40. Splenic infarction and bevacizumab.
Malka D; Van den Eynde M; Boige V; Dromain C; Ducreux M
Lancet Oncol; 2006 Dec; 7(12):1038. PubMed ID: 17138227
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
